UNIVERSAL TECHNICAL INSTITUT (UTI) Fundamental Analysis & Valuation

NYSE:UTI • US9139151040

36 USD
+0.71 (+2.01%)
At close: Mar 13, 2026
35.3 USD
-0.7 (-1.94%)
After Hours: 3/13/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This UTI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Taking everything into account, UTI scores 5 out of 10 in our fundamental rating. UTI was compared to 74 industry peers in the Diversified Consumer Services industry. While UTI has a great profitability rating, there are some minor concerns on its financial health. UTI is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

7

1. UTI Profitability Analysis

1.1 Basic Checks

  • In the past year UTI was profitable.
  • UTI had a positive operating cash flow in the past year.
  • In the past 5 years UTI has always been profitable.
  • Each year in the past 5 years UTI had a positive operating cash flow.
UTI Yearly Net Income VS EBIT VS OCF VS FCFUTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M

1.2 Ratios

  • With a decent Return On Assets value of 6.44%, UTI is doing good in the industry, outperforming 74.32% of the companies in the same industry.
  • UTI has a better Return On Equity (15.98%) than 75.68% of its industry peers.
  • UTI has a better Return On Invested Capital (8.69%) than 75.68% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for UTI is below the industry average of 10.83%.
  • The 3 year average ROIC (7.27%) for UTI is below the current ROIC(8.69%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.44%
ROE 15.98%
ROIC 8.69%
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
UTI Yearly ROA, ROE, ROICUTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 -20 -30

1.3 Margins

  • UTI has a better Profit Margin (6.28%) than 66.22% of its industry peers.
  • UTI's Profit Margin has improved in the last couple of years.
  • With a decent Operating Margin value of 8.38%, UTI is doing good in the industry, outperforming 64.86% of the companies in the same industry.
  • In the last couple of years the Operating Margin of UTI has grown nicely.
  • The Gross Margin of UTI (49.62%) is comparable to the rest of the industry.
  • UTI's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 8.38%
PM (TTM) 6.28%
GM 49.62%
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
UTI Yearly Profit, Operating, Gross MarginsUTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. UTI Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), UTI is creating some value.
  • Compared to 1 year ago, UTI has more shares outstanding
  • Compared to 5 years ago, UTI has more shares outstanding
  • Compared to 1 year ago, UTI has an improved debt to assets ratio.
UTI Yearly Shares OutstandingUTI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
UTI Yearly Total Debt VS Total AssetsUTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • UTI has an Altman-Z score of 3.88. This indicates that UTI is financially healthy and has little risk of bankruptcy at the moment.
  • UTI has a Altman-Z score of 3.88. This is in the better half of the industry: UTI outperforms 78.38% of its industry peers.
  • The Debt to FCF ratio of UTI is 6.28, which is on the high side as it means it would take UTI, 6.28 years of fcf income to pay off all of its debts.
  • UTI has a Debt to FCF ratio of 6.28. This is in the better half of the industry: UTI outperforms 72.97% of its industry peers.
  • UTI has a Debt/Equity ratio of 0.29. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.29, UTI is in line with its industry, outperforming 58.11% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF 6.28
Altman-Z 3.88
ROIC/WACC1
WACC8.67%
UTI Yearly LT Debt VS Equity VS FCFUTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • UTI has a Current Ratio of 1.14. This is a normal value and indicates that UTI is financially healthy and should not expect problems in meeting its short term obligations.
  • UTI has a Current ratio (1.14) which is comparable to the rest of the industry.
  • UTI has a Quick Ratio of 1.14. This is a normal value and indicates that UTI is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.14, UTI is in line with its industry, outperforming 51.35% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 1.14
UTI Yearly Current Assets VS Current LiabilitesUTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. UTI Growth Analysis

3.1 Past

  • The earnings per share for UTI have decreased by 0.00% in the last year.
  • UTI shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 65.96% yearly.
  • The Revenue has grown by 12.59% in the past year. This is quite good.
  • UTI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.67% yearly.
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%

3.2 Future

  • UTI is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.89% yearly.
  • UTI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.84% yearly.
EPS Next Y-31.19%
EPS Next 2Y-10.25%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue Next Year9.48%
Revenue Next 2Y8.85%
Revenue Next 3Y8.84%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
UTI Yearly Revenue VS EstimatesUTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M 800M 1B
UTI Yearly EPS VS EstimatesUTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 -1

More info and screens

Find the best growth stocksShow best growing peers

2

4. UTI Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 37.11, the valuation of UTI can be described as expensive.
  • UTI's Price/Earnings is on the same level as the industry average.
  • Compared to an average S&P500 Price/Earnings ratio of 25.70, UTI is valued a bit more expensive.
  • With a Price/Forward Earnings ratio of 39.20, UTI can be considered very expensive at the moment.
  • UTI's Price/Forward Earnings is on the same level as the industry average.
  • UTI is valuated expensively when we compare the Price/Forward Earnings ratio to 23.84, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 37.11
Fwd PE 39.2
UTI Price Earnings VS Forward Price EarningsUTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as UTI.
  • UTI's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. UTI is cheaper than 60.81% of the companies in the same industry.
Industry RankSector Rank
P/FCF 122.73
EV/EBITDA 17.16
UTI Per share dataUTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The decent profitability rating of UTI may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.56
EPS Next 2Y-10.25%
EPS Next 3Y5.89%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. UTI Dividend Analysis

5.1 Amount

  • No dividends for UTI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

UTI Fundamentals: All Metrics, Ratios and Statistics

UNIVERSAL TECHNICAL INSTITUT

NYSE:UTI (3/13/2026, 8:04:00 PM)

After market: 35.3 -0.7 (-1.94%)

36

+0.71 (+2.01%)

Chartmill FA Rating
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)02-04
Earnings (Next)05-05
Inst Owners97.17%
Inst Owner Change7.31%
Ins Owners2.7%
Ins Owner Change3.59%
Market Cap1.98B
Revenue(TTM)855.03M
Net Income(TTM)53.69M
Analysts81.82
Price Target38.42 (6.72%)
Short Float %5.23%
Short Ratio3.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.03
Dividend Growth(5Y)-34.43%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.57%
Min EPS beat(2)28.91%
Max EPS beat(2)66.22%
EPS beat(4)4
Avg EPS beat(4)59.42%
Min EPS beat(4)28.91%
Max EPS beat(4)73.27%
EPS beat(8)7
Avg EPS beat(8)48.68%
EPS beat(12)11
Avg EPS beat(12)85.96%
EPS beat(16)14
Avg EPS beat(16)183.11%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.47%
Max Revenue beat(2)0.82%
Revenue beat(4)4
Avg Revenue beat(4)1.74%
Min Revenue beat(4)0.47%
Max Revenue beat(4)4.51%
Revenue beat(8)8
Avg Revenue beat(8)2.01%
Revenue beat(12)12
Avg Revenue beat(12)2.35%
Revenue beat(16)15
Avg Revenue beat(16)2.9%
PT rev (1m)0.64%
PT rev (3m)0.64%
EPS NQ rev (1m)-103.86%
EPS NQ rev (3m)-103.82%
EPS NY rev (1m)0.72%
EPS NY rev (3m)-1.83%
Revenue NQ rev (1m)-0.41%
Revenue NQ rev (3m)-0.45%
Revenue NY rev (1m)0.21%
Revenue NY rev (3m)0.38%
Valuation
Industry RankSector Rank
PE 37.11
Fwd PE 39.2
P/S 2.32
P/FCF 122.73
P/OCF 25.57
P/B 5.9
P/tB 6.92
EV/EBITDA 17.16
EPS(TTM)0.97
EY2.69%
EPS(NY)0.92
Fwd EY2.55%
FCF(TTM)0.29
FCFY0.81%
OCF(TTM)1.41
OCFY3.91%
SpS15.54
BVpS6.11
TBVpS5.21
PEG (NY)N/A
PEG (5Y)0.56
Graham Number11.54
Profitability
Industry RankSector Rank
ROA 6.44%
ROE 15.98%
ROCE 11.63%
ROIC 8.69%
ROICexc 11.82%
ROICexgc 13.27%
OM 8.38%
PM (TTM) 6.28%
GM 49.62%
FCFM 1.89%
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
ROICexc(3y)10.21%
ROICexc(5y)8.25%
ROICexgc(3y)11.54%
ROICexgc(5y)9.21%
ROCE(3y)9.72%
ROCE(5y)7.88%
ROICexgc growth 3Y34.26%
ROICexgc growth 5YN/A
ROICexc growth 3Y33.76%
ROICexc growth 5YN/A
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
F-Score7
Asset Turnover1.03
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF 6.28
Debt/EBITDA 0.93
Cap/Depr 181.06%
Cap/Sales 7.17%
Interest Coverage 13.88
Cash Conversion 73.39%
Profit Quality 30.06%
Current Ratio 1.14
Quick Ratio 1.14
Altman-Z 3.88
F-Score7
WACC8.67%
ROIC/WACC1
Cap/Depr(3y)145.01%
Cap/Depr(5y)268.95%
Cap/Sales(3y)5.89%
Cap/Sales(5y)11.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
EPS Next Y-31.19%
EPS Next 2Y-10.25%
EPS Next 3Y5.89%
EPS Next 5YN/A
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%
Revenue Next Year9.48%
Revenue Next 2Y8.85%
Revenue Next 3Y8.84%
Revenue Next 5YN/A
EBIT growth 1Y-0.64%
EBIT growth 3Y47.33%
EBIT growth 5YN/A
EBIT Next Year46.18%
EBIT Next 3Y27.41%
EBIT Next 5YN/A
FCF growth 1Y371.76%
FCF growth 3YN/A
FCF growth 5Y99.08%
OCF growth 1Y35.47%
OCF growth 3Y28.35%
OCF growth 5Y54.57%

UNIVERSAL TECHNICAL INSTITUT / UTI FAQ

What is the fundamental rating for UTI stock?

ChartMill assigns a fundamental rating of 5 / 10 to UTI.


What is the valuation status for UTI stock?

ChartMill assigns a valuation rating of 2 / 10 to UNIVERSAL TECHNICAL INSTITUT (UTI). This can be considered as Overvalued.


Can you provide the profitability details for UNIVERSAL TECHNICAL INSTITUT?

UNIVERSAL TECHNICAL INSTITUT (UTI) has a profitability rating of 7 / 10.


Can you provide the financial health for UTI stock?

The financial health rating of UNIVERSAL TECHNICAL INSTITUT (UTI) is 5 / 10.


What is the earnings growth outlook for UNIVERSAL TECHNICAL INSTITUT?

The Earnings per Share (EPS) of UNIVERSAL TECHNICAL INSTITUT (UTI) is expected to decline by -31.19% in the next year.